查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840813

即時血糖值檢測市場：產品類型、最終用戶、分銷管道、檢測類型、技術和便攜性—2025-2032年全球預測

Point-of-Care Glucose Testing Market by Product Type, End User, Distribution Channel, Test Type, Technology, Portability - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，即時血糖值檢測 (POC) 市場規模將達到 131 億美元，複合年成長率為 7.77%。

關鍵市場統計數據
基準年 2024 72億美元
預計年份：2025年 77.7億美元
預測年份 2032 131億美元
複合年成長率 (%) 7.77%

權威地指導如何利用融合技術、數位系統和以患者為中心的醫療保健服務來重塑即時血糖值檢測和護理路徑。

即時血糖值檢測（POC​​）在現代糖尿病診療流程中扮演核心角色，其速度、準確性和便利性直接決定臨床療效和患者的生活品質。過去十年，臨床實踐和消費者期望推動診斷方式從一次性實驗室檢測發展到持續的、近患者的監測，從而支持即時治療決策和遠距醫療模式。這一轉變得益於多個領域的進步：感測器化學和光電的進步提高了訊號保真度；小型化電子元件和連接技術實現了連續的數據流；可互通的軟體應用將血糖值測量數據轉化為具有臨床意義的洞察。

因此，整個生態系統中的相關人員正在重新調整優先事項。設備製造商正在平衡對傳統血糖值儀和試紙的投資，同時拓展產品組合，納入連續血糖值監測設備和配套感測器。醫療系統和支付方正在評估門診手術中心和醫院實驗室在臨床和營運方面的權衡，而居家輔助和自我監測模式的興起正在重塑分銷管道。同時，對非侵入性和微創檢測的日益重視，以及比色法、電化學法和光強度等不同技術方法的應用，正在拓寬創新成果惠及臨床醫生和消費者的途徑。

因此，即時血糖值檢測不再只是實驗室層面的問題，而是一個與數位醫療、零售分銷和醫療服務模式重塑密切相關的策略領域。本報告綜合分析了這些交叉領域，旨在幫助臨床領導者、研發團隊和商業負責人清晰地了解複雜的市場格局，並做出能夠協調產品開發、通路策略和監管環境的決策，從而最大限度地發揮其臨床和經濟效益。

即時監測、混合分銷模式、感測器創新和整合軟體平台如何改變血糖值檢測領域的競爭格局和臨床動態

即時血糖值檢測（POC​​）領域正經歷變革時期，這場變革正在重新定義競爭格局、臨床工作流程和病患期望。即時連續血糖值監測已從一種專業工具發展成為臨床主流，實現了主動血糖控制和遠端患者管理。這推動了感測器多樣化方面的投資；雖然酵素感測器仍然是許多應用的基礎，但新的光學方法旨在降低侵入性並提高使用者舒適度。同時，軟體應用也從被動記錄工具發展成為整合平台，能夠為醫療團隊提供決策支援、遠端檢測以及演算法主導的警報，從而減少急性事件的發生。

同時，分銷動態正向混合模式轉變，整合了直銷、醫院和零售藥房網路，以及日益成熟的線上藥局管道，包括製造商商店和第三方平台。家庭監測（包括自助式和輔助式）的興起，迫使製造商優先考慮便攜性和以用戶為中心的設計，而桌上型平台則繼續推動診斷實驗室和大型醫院的安裝。診斷實驗室本身也分為醫院附屬機構和獨立機構，各自擁有不同的採購週期和臨床整合挑戰。監管和報銷政策的變化進一步加劇了這種轉變的複雜性，推動了設備製造商、醫療系統和數位醫療供應商之間的跨產業夥伴關係。

綜上所述，這些變革力量要求企業採取策略性應對措施，將產品差異化、分銷創新和臨床證據生成結合。業界參與者若能使其感測器技術選擇（例如電化學、光度、比色等）與終端用戶的工作流程相匹配，並建立可互通的軟體層以支援臨床醫生和患者的決策，將更有利於獲得臨床應用並實現永續規模化。

2025年美國貿易政策調整對血糖值檢測產業的採購、製造佈局、分銷經濟效益和策略供應商風險管理的影響

美國在2025年前實施的關稅和貿易政策調整，正對即時檢測（POC​​）儀器和耗材的製造商選擇、籌資策略和全球供應鏈設計產生直接且連鎖的影響。半導體晶片、專用光學元件和化學試劑等組件可能需要經過多條國際供應鏈，而關稅波動會改變不同採購地點的相對經濟效益，促使企業重新評估其製造外包、生產本地化和庫存策略。因此，除了傳統的品質和成本指標外，採購團隊正在重新重視將貿易風險和物流韌性納入供應商資格評估標準。

實際上，企業正在透過供應商多元化和尋求區域性生產佈局來應對關稅影響，同時確保關鍵零件的供應。對於試紙等低淨利率產品而言，關稅帶來的成本壓力尤其顯著，促使企業加快與分銷合作夥伴的談判，重新評估定價框架和付款條款。而以軟體為中心的產品和雲端基礎服務則呈現不同的趨勢。由於對實體組件的依賴性較低，這些解決方案透過分析、依從性計劃和遠端監控服務提供附加價值，使其成為能夠抵消硬體成本壓力的策略差異化因素。

此外，政策環境鼓勵產業參與者提高供應鏈透明度，更積極地與支付方和採購機構互動，並使報銷途徑與不斷變化的成本結構相符。雖然關稅本身並不能決定長期的競爭結果，但它們確實促使企業更加關注營運靈活性、供應商風險管理和戰略夥伴關係關係，並加速向以軟體和服務產品為主要收入來源的經營模式轉型，以此對沖硬體相關成本波動帶來的風險。

策略性細分分析揭示了產品架構、終端用戶工作流程、通路、檢測方式和便攜性選項如何影響產品採納和設計優先順序。

以細分市場主導的視角揭示了產品、終端用戶、分銷管道、檢測類型、技術和便攜性等各個維度上的細微機會和營運挑戰。按產品類型分類，連續血糖值監測設備包括間歇掃描系統和即時系統，這重新定義了人們對監測頻率和臨床醫生工作流程的預期。感測器方面，則分為兩類：一類是分析性能成熟的酵素法感測器，另一類是旨在實現微創性和提高使用者接受度的新型光學感測器。

就終端使用者而言，門診手術中心需要快速、可靠的照護現場結果，並將其整合到圍手術全期決策中；而醫院附屬和獨立診斷實驗室則需要標準化的工作流程和實驗室資訊系統連接。從大型醫院系統到小型診所，不同規模的醫院和診所的採購週期和臨床整合需求也各不相同。分銷管道涵蓋了支援臨床帳戶管理的直接面對消費者模式，以及優先考慮供應連續性的醫院和零售藥房；此外，無論是廠家自營的線上商店還是第三方平台，線上藥局在直接面對消費者方面的重要性也日益凸顯。

檢測類型分為侵入性、微創和非侵入性三種，每種類型都有其特定的監管和臨床證據要求，這些要求會影響研發進度和市場推廣。技術選擇——比色法、電化學法或光強度——需要在性能、成本和可製造性之間進行權衡，並且必須根據特定應用場景進行客製化。便攜性（桌上型或可攜式）也會影響產品設計和目標使用者。總體而言，最成功的產品策略是將感測器化學和檢測形式與目標終端使用者的工作流程和通路相匹配，並輔以能夠減少摩擦、增強臨床效用的軟體功能。

美洲、歐洲、中東和非洲以及亞太地區的管理體制制度、支付方動態、生產佈局和通路偏好將如何決定其普及路徑

區域動態在即時檢測（POC​​）生態系統中對臨床應用、監管策略和供應鏈選擇起著至關重要的作用。在美洲，醫療保健服務的特點是高度重視門診和家庭監測，持續血糖值監測技術已快速普及，以及商業環境中支付方談判和價值論證對於規模化至關重要。監管流程和報銷結構因國家和地區而異，因此需要製定獨特的證據生成和定價策略，以滿足公共和私人購買方的需求。

在歐洲、中東和非洲，監管協調工作和多樣化的醫療保健基礎設施既帶來了機遇，也帶來了挑戰。西方市場通常對臨床證據和互通性有著很高的標準，而中東和非洲部分地區則更注重價格可負擔性和供應鏈的穩健性，鼓勵透過夥伴關係實現在地化的組裝和分銷。相較之下，亞太地區則呈現高度異質性，技術應用迅速，國內製造能力強大，但管理體制卻各不相同。在一些經濟體中，本地製造商是關鍵參與者，採購受到國家產業政策的影響。在各個地區，線上藥局、直銷銷售管道和零售藥局網路的普及程度影響著醫療器材和耗材的到達患者手中的方式，而臨床實踐指南的區域差異也決定了持續監測和階段性監測的優先事項。

因此，希望拓展國際市場的公司必須制定反映區域特殊性的監管、商業和供應鏈策略，投資於本地證據生成，建立與醫院和藥房採購模式相一致的分銷關係，並在適當情況下建立本地製造或組裝能力，以縮短前置作業時間並減輕關稅的影響。

差異化產品組合、數位生態系統整合、通路策略和供應鏈韌性如何塑造領先血糖檢測公司的競爭優勢

主要企業之間的競爭動態正日益受到產品組合廣度、數位生態系統整合以及在不同醫療環境中提供臨床療效的能力的影響。市場領先的設備製造商正致力於拓展連續血糖值監測功能，同時保持其在血糖值儀和試紙的領先地位，以滿足各種臨床需求。與軟體開發商和遠端醫療服務提供者建立策略聯盟，使設備供應商能夠提供護理管理服務，從而提高患者依從性、支持遠端劑量調整，並產生真實世界證據以增強醫保報銷。

同時，規模較小的利基企業正瞄準差異化的感測器技術，包括光學感測器和新型微創技術，以搶佔專業應用領域，並成為尋求技術加速發展的大型企業的收購目標。分銷策略各不相同，一些公司強調直銷和與醫院藥房的合作關係，以確保機構採用；而另一些公司則追求全通路銷售，利用零售藥房網路和在線市場觸達消費者。供應鏈韌性，包括雙源採購和區域製造，已成為一項策略重點，擁有健全的品質系統和靈活生產能力的公司更有能力應對組件差異化問題。總而言之，能夠將硬體、軟體、服務和管道執行整合為連貫提案的公司，將在說服臨床醫生、支付方和患者相信其產品的持久價值方面佔據優勢。

為醫療器材製造商和商業團隊提供可操作的策略重點，以加速產品推廣、分散風險，並使產品創新與支付方和臨床需求保持一致。

產業領導者應採取多維策略，優先考慮技術多元化、通路創新和營運韌性，以實現成長並降低風險。首先，應有選擇地投資先進的感測器技術，以降低侵入性並改善用戶體驗，同時保持分析的穩健性；此外，還應開發模組化架構，以便快速整合新的感測器化學成分和光學元件。其次，應透過建構可互通的軟體平台來擴展數位化能力，這些平台可提供臨床醫生決策支援、病人參與工具、依從性計畫等功能，從而創造可抵銷硬體利潤壓力的經常性收入來源。

此外，為降低貿易政策衝擊和物流中斷的風險，我們將實現生產和供應商佈局多元化，並考慮在地化生產和組裝，以縮短關鍵耗材的前置作業時間。我們將加強與醫院、診斷實驗室（包括院內實驗室和獨立實驗室）以及藥房網路（包括廠商營運的線上管道和第三方夥伴關係）的合作，建構均衡的分銷管道，涵蓋門診手術中心、居家醫療機構以及各種規模的診所。最後，我們將儘早與監管機構和支付方溝通，並制定循證醫學方案，以證明有創、微創和非侵入性檢測方式的臨床效用和成本效益，並將情境規劃納入商業預測，以確保在政策和報銷政策變化時能夠靈活應對。

透過嚴謹的混合方法研究框架檢驗可操作的洞見，該框架結合了相關人員訪談、監管和專利研究、臨床文獻綜述以及供應鏈情境測試。

本報告的分析將一手定性研究成果與全面的二手證據相結合，從而對臨床、商業和技術動態有了深入的了解。一手研究包括對臨床醫生、採購負責人、診斷實驗室經理、居家照護提供者、連鎖藥店負責人和製造企業高管進行結構化訪談，以收集第一線人員對設備性能、工作流程整合和分銷偏好的觀點。這些研究成果與監管文件、同行評審的臨床研究、設備核准摘要、專利概況分析和技術可行性評估進行三角驗證，以檢驗技術聲明和應用促進因素。

調查方法採用細分框架，涵蓋產品類型、最終用戶、分銷管道、測試類型、技術和便攜性，以確保研究結果能夠應用於具體的商業策略。透過供應商映射和基於情境的影響評估，進行了供應鏈和關稅敏感性分析，以識別營運漏洞並制定相應的緩解措施。最後，本研究與相關領域的專家舉辦了內部檢驗研討會，以確定策略意義的優先順序，並確保建議符合臨床實際情況和商業性限制。

本文簡要概述了技術進步、漸進式分銷和供應鏈韌性如何共同構成糖尿病護理相關人員的策略要務。

即時血糖檢測正處於曲折點，技術創新、不斷發展的醫療服務模式和不斷變化的商業性格局既帶來了機遇，也帶來了挑戰。連續監測技術、感測器化學和光學技術的進步以及功能更強大的軟體生態系統，正推動著從一次性測量向持續、一體化的醫療管理模式的轉變。同時，不斷演變的銷售管道——包括直銷、醫院、零售藥局和線上市場——以及關稅調整等政策動態，正迫使商業領袖在採購、定價和通路策略中融入靈活性。

最終，能夠在這種環境下取得成功的組織，將是那些能夠將產品設計與目標終端用戶的工作流程相匹配、利用軟體和服務提升臨床價值，以及建立能夠降低貿易和物流風險的彈性供應鏈的組織。透過結合精準的市場區隔、基於地理位置的策略以及嚴謹的證據生成，相關人員可以將這種變革時期轉化為永續的競爭優勢，並最終改善糖尿病患者的治療效果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 快速推廣使用採用先進光學技術的非侵入式血糖值感測器可提高患者依從性。
  • 人工智慧驅動的分析技術擴展了智慧型手機連接的血糖值檢測功能，可提供個人化的胰島素劑量建議。
  • 可攜式連續血糖值監測穿戴式貼片的普及，使得與健康應用程式的即時數據整合成為可能。
  • 開發一種多功能即時檢測設備，該設備可測量血糖值以及其他生物標記物，以進行全面的代謝分析。
  • 將血糖值監測系統與遠端醫療相結合的應用激增，從而實現了遠距醫生干預和數據共用。
  • 擴大醫療器材製造商和製藥公司之間的合作，以開發糖尿病護理的伴隨診斷技術
  • 支援雲端基礎資料管理和預測分析的物聯網（IoMT）血糖值檢測設備的出現

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的即時血糖值檢測市場

  • 連續血糖監測設備
    • 間歇掃描
    • 即時的
  • 血糖值監測儀
  • 感應器
    • 酵素
    • 光學
  • 軟體應用
  • 測試條

9. 依最終用戶分類的即時血糖值檢測市場

  • 門診手術中心
  • 診斷實驗室
    • 醫院實驗室
    • 獨立實驗室
  • 居家照護
    • 居家護理支援
    • 自我監測
  • 醫院和診所
    • 大型醫院
    • 小診所

第10章 按分銷管道分類的即時血糖值檢測市場

  • 直銷
  • 醫院藥房
  • 網路藥房
    • 製造商網站
    • 第三方市場
  • 零售藥房

第11章 依檢測類型分類的即時血糖值檢測市場

  • 侵入性
  • 微創
  • 非侵入性

第12章 依技術分類的即時血糖值檢測市場

  • 比色分析
  • 電化學
  • 光度學

第13章 即時血糖值檢測市場：移動性別

  • 工作台
  • 可攜式的

第14章 各地區的即時血糖值檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 依群體分類的即時血糖值檢測市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國即時血糖值檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd
    • Dexcom, Inc.
    • Medtronic plc
    • Johnson & Johnson
    • Ascensia Diabetes Care Holdings AG
    • Nova Biomedical Corporation
    • Becton, Dickinson and Company
    • Sinocare Inc.
    • Nipro Corporation
Product Code: MRR-B9334AD6C44F

The Point-of-Care Glucose Testing Market is projected to grow by USD 13.10 billion at a CAGR of 7.77% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.20 billion
Estimated Year [2025] USD 7.77 billion
Forecast Year [2032] USD 13.10 billion
CAGR (%) 7.77%

An authoritative orientation to how converging technologies, digital systems, and patient-centric delivery are reshaping point-of-care glucose testing and care pathways

Point-of-care glucose testing occupies a central role in contemporary diabetes care pathways, where speed, accuracy, and accessibility determine clinical outcomes and patient quality of life. Over the past decade clinical practice and consumer expectations have pushed diagnostics from episodic laboratory tests toward continuous, near-patient monitoring that supports real-time therapeutic decisions and remote care models. This evolution has been driven by advances across multiple domains: sensor chemistry and photonics that improve signal fidelity, miniaturized electronics and connectivity that enable persistent data flows, and interoperable software applications that translate streams of glucose readings into clinically actionable insights.

Consequently, stakeholders across the ecosystem are recalibrating priorities. Device manufacturers are balancing investments between traditional glucose meters and test strips, while expanding portfolios to include continuous glucose monitoring devices and complementary sensors. Health systems and payers are evaluating the clinical and operational trade-offs of ambulatory surgical centers versus hospital-based laboratories, and the rise of assisted and self-monitoring paradigms at home is reshaping distribution choices. In parallel, a growing emphasis on non-invasive and minimally invasive test types, coupled with distinct technology approaches such as colorimetric, electrochemical, and photometric methods, is broadening the pathways through which innovation can reach clinicians and consumers.

As a result, point-of-care glucose testing is no longer solely a laboratory concern but a strategic domain that intersects with digital health, retail distribution, and care delivery redesign. This report synthesizes those intersections so clinical leaders, R&D teams, and commercial strategists can navigate the complex landscape with clarity and make decisions that align product development, channel strategy, and regulatory engagement for maximal clinical and economic impact.

How real-time monitoring, hybrid distribution models, sensor innovation, and integrated software platforms are collectively transforming competitive and clinical dynamics in glucose testing

The landscape of point-of-care glucose testing is undergoing transformative shifts that are redefining competitive boundaries, clinical workflows, and patient expectations. Real-time continuous glucose monitoring has moved from a specialized tool into mainstream clinical practice, enabling proactive glycemic control and remote patient management. This has catalyzed investment in sensor diversity, where enzymatic sensors remain foundational for many applications while emerging optical approaches aim to reduce invasiveness and improve user comfort. At the same time, software applications have matured from passive logging tools into integrated platforms that enable decision support, telemetry to care teams, and algorithm-driven alerts that reduce acute events.

Concurrently, distribution dynamics are shifting toward hybrid models that blend direct sales, hospital and retail pharmacy networks, and increasingly sophisticated online pharmacy channels that include manufacturer storefronts and third-party marketplaces. The rise of home-based monitoring, both self-managed and assisted, is prompting manufacturers to prioritize portability and user-centric design, while benchtop platforms continue to serve diagnostic laboratories and large hospital installations. Diagnostic laboratories themselves are segmented into hospital-based and independent facilities, creating differentiated procurement cycles and clinical integration challenges. These shifts are compounded by regulatory and reimbursement changes that are encouraging cross-sector partnerships between device companies, health systems, and digital health vendors.

Taken together, these transformative movements demand a strategic response that combines product differentiation, distribution innovation, and clinical evidence generation. Industry participants who align sensor technology choices-whether electrochemical, photometric, or colorimetric-with targeted end-user workflows, and who build interoperable software layers to support clinician and patient decision-making, will be better positioned to capture clinical adoption and scale sustainably.

Implications of 2025 United States trade policy adjustments on sourcing, manufacturing footprints, distribution economics, and strategic supplier risk management in glucose testing

The introduction of tariffs and trade policy adjustments in the United States during 2025 has had immediate and cascading implications across manufacturing choices, procurement strategies, and global supply chain design for devices and consumables used in point-of-care glucose testing. Components such as semiconductor chips, specialized optics, and chemical reagents can traverse multiple international supply chains, and tariff shifts alter the relative economics of sourcing locations, incentivizing companies to reassess contract manufacturing, localization of production, and inventory strategies. Consequently, procurement teams have reprioritized supplier qualification criteria to include trade exposure and logistics resilience alongside traditional quality and cost metrics.

In practical terms, companies have responded by diversifying supplier bases and exploring regional manufacturing footprints that can mitigate tariff exposure while preserving access to critical components. For products with thinner margins, such as test strips, tariff-driven cost pressure is particularly acute and has accelerated negotiations with distribution partners to re-evaluate pricing frameworks and payment terms. Software-centric offerings and cloud-based services have experienced a different dynamic; with lower physical component dependence, these solutions have become strategic differentiators that can offset hardware cost pressures by delivering added value through analytics, adherence programs, and remote monitoring services.

Moreover, the policy environment has nudged industry participants to improve transparency in their supply chains and to engage more proactively with payers and procurement bodies to align reimbursement pathways with evolving cost structures. While tariffs alone do not determine long-term competitive outcomes, they have sharpened focus on operational agility, supplier risk management, and strategic partnerships, and they have accelerated a shift toward business models that emphasize recurring revenue through software and service offerings as a hedge against hardware-related cost volatility.

Strategic segmentation analysis revealing how product architectures, end-user workflows, distribution pathways, assay modalities, and portability choices shape adoption and design priorities

A segmentation-driven lens reveals nuanced opportunities and operational challenges across product, end user, distribution, test type, technology, and portability dimensions. In product type, continuous glucose monitoring devices, which encompass both intermittently scanned and real-time systems, are redefining expectations around monitoring frequency and clinician workflows, while traditional glucose meters and test strips remain vital for point checks and settings where continuous monitoring is less practical. Sensors present a bifurcation between enzymatic approaches with well-established analytical performance and newer optical sensors that aim to achieve lower invasiveness and improved user acceptance; software applications increasingly serve as the integrative layer that translates raw readings into management pathways.

With respect to end users, ambulatory surgical centers demand rapid, reliable point-of-care results integrated into perioperative decision-making, whereas diagnostic laboratories-both hospital-based and independent-require standardized workflows and connectivity for lab information systems. Home care has bifurcated into assisted home care and self-monitoring populations, each with distinct usability and support needs, and hospitals and clinics, spanning large hospital systems to small clinics, have contrasting procurement cycles and clinical integration requirements. Distribution channels vary from direct sales models that support clinical account management to hospital pharmacies and retail pharmacies that prioritize supply continuity, while online pharmacies, whether manufacturer-operated storefronts or third-party marketplaces, are increasingly important for direct-to-consumer access.

Test types, categorized into invasive, minimally invasive, and non-invasive methodologies, create specific regulatory and clinical evidence demands that shape development timelines and adoption curves. Technology choices-colorimetric, electrochemical, and photometric-bring different performance, cost, and manufacturability trade-offs that must be matched to intended use cases. Portability considerations, whether benchtop or portable, further influence product design and target audiences. In synthesis, the most successful product strategies will be those that align sensor chemistry and assay format with targeted end-user workflows and distribution pathways, supported by software features that reduce friction and enhance clinical utility.

How regional regulatory regimes, payer dynamics, manufacturing footprints, and channel preferences across the Americas, Europe Middle East & Africa, and Asia-Pacific determine adoption pathways

Regional dynamics play a decisive role in shaping clinical adoption, regulatory strategies, and supply chain choices across the point-of-care glucose testing ecosystem. In the Americas, care delivery is characterized by a strong emphasis on outpatient and home-based monitoring, rapid adoption of continuous glucose monitoring technologies, and a commercial environment where payer negotiation and value demonstration are critical for scale. Regulatory processes and reimbursement mechanisms vary between national and subnational payers, necessitating tailored evidence generation and pricing strategies that resonate with both public and private purchasers.

Within Europe, Middle East & Africa, regulatory harmonization efforts and diversified healthcare infrastructure create both opportunities and complexity. Western European markets often exhibit high standards for clinical evidence and interoperability, while parts of the Middle East and Africa emphasize affordability and supply chain robustness, encouraging partnerships that localize assembly or distribution. In contrast, Asia-Pacific is highly heterogeneous with pockets of rapid technological uptake, substantial domestic manufacturing capacity, and varying regulatory regimes; in some economies, local manufacturers are significant players and procurement is influenced by national industrial policies. Across all regions, online pharmacy penetration, direct-to-consumer channels, and retail pharmacy networks influence how devices and consumables reach patients, and regional differences in clinical practice guidelines shape the prioritization of continuous versus episodic monitoring.

Therefore, companies seeking international expansion must design regulatory, commercial, and supply chain strategies that reflect regional idiosyncrasies. This requires investing in localized evidence generation, building distribution relationships that align with hospital and pharmacy procurement models, and, where appropriate, establishing regional manufacturing or assembly capabilities to reduce lead times and mitigate tariff exposure.

How differentiated portfolios, digital ecosystem integration, channel strategies, and supply chain resilience are shaping competitive advantage among leading glucose testing companies

Competitive dynamics among leading companies are increasingly shaped by portfolio breadth, integration of digital ecosystems, and the ability to deliver clinical outcomes across diverse care settings. Market-leading device manufacturers have focused on extending continuous glucose monitoring capabilities while maintaining presence in glucose meters and test strip segments to serve a wide range of clinical scenarios. Strategic partnerships with software developers and telehealth providers have enabled device vendors to offer care management services that improve adherence, support remote titration of therapies, and generate real-world evidence that strengthens reimbursement cases.

At the same time, smaller and niche players are targeting differentiated sensor technologies, including optical and novel minimally invasive approaches, to capture specialist use cases and to create acquisition targets for larger firms seeking technological acceleration. Distribution strategies vary; some companies emphasize direct sales and hospital pharmacy relationships to secure institutional adoption, while others pursue omnichannel commercialization that leverages retail pharmacy networks and online marketplaces for consumer reach. Supply chain resilience, including dual sourcing and regional manufacturing, has become a strategic priority, and companies that combine robust quality systems with flexible manufacturing arrangements are better positioned to manage component volatility. Overall, firms that can integrate hardware, software, services, and channel execution into a coherent proposition will have an advantage in convincing clinicians, payers, and patients of the sustained value of their offerings.

Actionable strategic priorities for device makers and commercial teams to accelerate adoption, diversify risk, and align product innovation with payer and clinical needs

Industry leaders should adopt a multi-dimensional strategy that prioritizes technological diversification, channel innovation, and operational resilience to capture growth and mitigate risk. First, invest selectively in advancing sensor technologies that reduce invasiveness and improve user experience while preserving analytical robustness, and concurrently develop modular architectures that allow rapid integration of new sensor chemistries or optical components. Second, expand digital capabilities by building interoperable software platforms that deliver clinician decision support, patient engagement tools, and adherence programs, thereby creating recurring revenue streams that offset hardware margin pressures.

Additionally, diversify manufacturing and supplier footprints to reduce exposure to trade-policy shocks and logistics disruptions, and consider regional manufacturing or assembly to shorten lead times for critical consumables. Strengthen partnerships with hospitals, diagnostic laboratories-both hospital-based and independent-and pharmacy networks, including manufacturer-operated online channels and third-party marketplaces, to create a balanced distribution mix that reaches patients across ambulatory surgical centers, home care settings, and clinics of varying sizes. Finally, engage early with regulators and payers to design evidence-generation programs that demonstrate clinical utility and cost-effectiveness across invasive, minimally invasive, and non-invasive test modalities, and incorporate scenario planning into commercial forecasts to ensure agility in the face of policy or reimbursement shifts.

A rigorous mixed-methods research framework combining stakeholder interviews, regulatory and patent analysis, clinical literature review, and supply chain scenario testing to validate actionable insights

The analysis underpinning this report synthesizes primary qualitative insights with comprehensive secondary evidence to build a robust understanding of clinical, commercial, and technological dynamics. Primary research included structured interviews with clinicians, procurement leaders, diagnostic laboratory managers, home care providers, pharmacy chain strategists, and manufacturing executives to capture frontline perspectives on device performance, workflow integration, and distribution preferences. These insights were triangulated with regulatory filings, peer-reviewed clinical studies, device approval summaries, patent landscape reviews, and technology feasibility assessments to validate technical claims and adoption drivers.

Methodologically, the study applies a segmentation framework across product types, end users, distribution channels, test types, technologies, and portability to ensure findings are actionable for discrete commercial strategies. Supply chain and tariff sensitivity analyses were conducted using supplier mapping and scenario-based impact assessments to highlight operational vulnerabilities and mitigation options. Finally, the research was subjected to internal validation workshops with domain experts to prioritize strategic implications and to ensure the recommendations are aligned with clinical practice realities and commercial operational constraints.

A concise synthesis of how technological advances, distribution evolution, and supply chain resilience combine to create strategic imperatives for diabetes care stakeholders

Point-of-care glucose testing is at an inflection point where technological innovation, evolving care delivery models, and shifting commercial dynamics converge to create both opportunity and complexity. Continuous monitoring technologies, advances in sensor chemistry and optics, and more capable software ecosystems are enabling a shift from episodic measurement to continuous, integrated care management. At the same time, distribution evolution-spanning direct sales, hospital and retail pharmacies, and online marketplaces-and policy dynamics such as tariff adjustments require commercial leaders to build agility into their sourcing, pricing, and channel strategies.

Ultimately, success in this environment will favor organizations that can align product design with targeted end-user workflows, leverage software and services to amplify clinical value, and construct resilient supply chains that mitigate trade and logistics risk. By combining precise segmentation, regionally informed strategies, and disciplined evidence generation, stakeholders can convert the current period of change into a sustained competitive advantage and improved outcomes for patients living with diabetes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of non-invasive glucose sensors leveraging advanced optical technologies for improved patient compliance
  • 5.2. Expansion of smartphone-connected blood glucose meters with AI-driven analytics for personalized insulin dosing recommendations
  • 5.3. Growth of portable continuous glucose monitoring wearable patches offering real-time data integration with health apps
  • 5.4. Development of multiplexed point-of-care devices measuring glucose alongside other biomarkers for comprehensive metabolic profiling
  • 5.5. Surge in adoption of telemedicine-integrated glucose monitoring systems enabling remote clinician intervention and data sharing
  • 5.6. Increasing partnerships between device manufacturers and pharmaceutical companies to develop companion diagnostics for diabetes therapeutics
  • 5.7. Emergence of IoMT-enabled glucose testing devices supporting cloud-based data management and predictive analytics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point-of-Care Glucose Testing Market, by Product Type

  • 8.1. Continuous Glucose Monitoring Devices
    • 8.1.1. Intermittently Scanned
    • 8.1.2. Real Time
  • 8.2. Glucose Meters
  • 8.3. Sensors
    • 8.3.1. Enzymatic
    • 8.3.2. Optical
  • 8.4. Software Apps
  • 8.5. Test Strips

9. Point-of-Care Glucose Testing Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Diagnostic Laboratories
    • 9.2.1. Hospital Based Labs
    • 9.2.2. Independent Labs
  • 9.3. Home Care
    • 9.3.1. Assisted Home Care
    • 9.3.2. Self Monitoring
  • 9.4. Hospitals & Clinics
    • 9.4.1. Large Hospitals
    • 9.4.2. Small Clinics

10. Point-of-Care Glucose Testing Market, by Distribution Channel

  • 10.1. Direct Sales
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
    • 10.3.1. Manufacturer Websites
    • 10.3.2. Third Party Marketplaces
  • 10.4. Retail Pharmacies

11. Point-of-Care Glucose Testing Market, by Test Type

  • 11.1. Invasive
  • 11.2. Minimally Invasive
  • 11.3. Non Invasive

12. Point-of-Care Glucose Testing Market, by Technology

  • 12.1. Colorimetric
  • 12.2. Electrochemical
  • 12.3. Photometric

13. Point-of-Care Glucose Testing Market, by Portability

  • 13.1. Benchtop
  • 13.2. Portable

14. Point-of-Care Glucose Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Point-of-Care Glucose Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Point-of-Care Glucose Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. F. Hoffmann-La Roche Ltd
    • 17.3.3. Dexcom, Inc.
    • 17.3.4. Medtronic plc
    • 17.3.5. Johnson & Johnson
    • 17.3.6. Ascensia Diabetes Care Holdings AG
    • 17.3.7. Nova Biomedical Corporation
    • 17.3.8. Becton, Dickinson and Company
    • 17.3.9. Sinocare Inc.
    • 17.3.10. Nipro Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. POINT-OF-CARE GLUCOSE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. POINT-OF-CARE GLUCOSE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. POINT-OF-CARE GLUCOSE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA POINT-OF-CARE GLUCO